Vesugen

Vesugen — Vascular Endothelium Bioregulator

Vesugen is a Khavinson-class short-chain bioregulator peptide that restores youthful gene expression in vascular endothelium tissue.

Peptide Specifications

Parameter	Value
Sequence	Lys-Glu-Asp
Mass	390.4 g/mol
Purity	>98.0%
Target Organ	Vascular Endothelium

Figure 1: Vesugen Organ-Specific Bioregulation

Tissue-Specific Mechanism

1. Tripeptide with tropism for vascular endothelial tissue.
2. Repairs endothelial dysfunction by restoring eNOS expression.
3. Normalizes arterial compliance and peripheral resistance.
4. Reduces atherosclerotic plaque formation.
5. Rebuilds the protective glycocalyx lining blood vessels.

Figure 2: Vascular Endothelium Regeneration Curve

Research Results

• 1: Defining Khavinson bioregulator for cardiovascular health.
• 2: Normalizes blood pressure in hypertensive models.
• 3: Unmatched vascular wall restoration at molecular level.

Vascular Endothelial Bioregulator

Vesugen (Lys-Glu-Asp) is a synthetic tripeptide bioregulator targeting vascular endothelial cells. Endothelial dysfunction is now recognized as the earliest detectable event in atherosclerosis and cardiovascular disease, preceding plaque formation by decades. Vesugen restores endothelial gene expression patterns toward youthful profiles, normalizing nitric oxide production, anti-thrombotic surface properties, and vascular permeability regulation. This epigenetic approach to vascular health addresses the root cause of age-related cardiovascular decline rather than treating downstream consequences.

1. Vesugen enters endothelial cell nuclei and modulates chromatin structure at promoter regions of endothelial nitric oxide synthase (eNOS/NOS3).
2. eNOS expression is upregulated, restoring NO production and NO-dependent vasodilation that declines with aging.
3. Thrombomodulin and prostacyclin (PGI2) synthase expression is normalized, maintaining the endothelial anti-thrombotic surface.
4. Adhesion molecule expression (VCAM-1, ICAM-1, E-selectin) is downregulated, reducing inflammatory leukocyte recruitment to the vessel wall.
5. Endothelial barrier function genes (VE-cadherin, claudin-5) are restored, reducing vascular permeability and edema.

Cardiovascular Research Applications

• Endothelial Function: Flow-mediated dilation (FMD) measurements in aged subjects show improvement after Vesugen course administration, indicating restored NO bioavailability.
• Atherosclerosis Prevention: By normalizing endothelial adhesion molecule expression, Vesugen may reduce the earliest steps of atherogenesis—monocyte adhesion and subendothelial migration.
• Hypertension: Restored eNOS function contributes to improved vascular compliance and blood pressure regulation in aged vascular models.
• Combination: Often combined with Cardiogen (cardiac bioregulator) for comprehensive cardiovascular bioregulator protocols.
• Protocol: 1–2 capsules daily for 20–30 days. Course repeated every 3–6 months for maintenance of vascular endothelial function.